Article
Immunology
Felix Wussow, Mindy Kha, Taehyun Kim, Minh Ly, Marcal Yll-Pico, Swagata Kar, Mark G. G. Lewis, Flavia Chiuppesi, Don J. J. Diamond
Summary: Researchers developed a vaccine called COH04S1, which provides protection against SARS-CoV-2 Omicron subvariants and other variants. The vaccine has shown safety and immunogenicity in animal models and clinical trials. The study demonstrates the efficacy of COH04S1 and variant-specific vaccines in providing cross-protective immunity.
Article
Immunology
Robbert Boudewijns, Patricia Perez, Adrian Lazaro-Frias, Dominique Van Looveren, Thomas Vercruysse, Hendrik Jan Thibaut, Birgit Weynand, Lotte Coelmont, Johan Neyts, David Astorgano, Dolores Montenegro, Eugenia Puentes, Esteban Rodriguez, Kai Dallmeier, Mariano Esteban, Juan Garcia-Arriaza
Summary: This study reports the potent immunogenicity and efficacy of a vaccine candidate based on a modified vaccinia virus Ankara (MVA) vector in hamsters. The vaccine induced high levels of neutralizing antibodies against SARS-CoV-2 and its variants, and resulted in reduced viral RNA and infectious virus in the lungs of vaccinated hamsters. These findings support the potential use of MVA-S as a vaccine candidate for SARS-CoV-2.
FRONTIERS IN IMMUNOLOGY
(2022)
Article
Immunology
Rana Abdelnabi, Patricia Perez, David Astorgano, Guillermo Albericio, Winnie Kerstens, Hendrik Jan Thibaut, Lotte Coelmont, Birgit Weynand, Nuria Labiod, Rafael Delgado, Dolores Montenegro, Eugenia Puentes, Esteban Rodriguez, Johan Neyts, Kai Dallmeier, Mariano Esteban, Juan Garcia-Arriaza
Summary: This study describes the enhanced immunogenicity and efficacy of the MVA-S(3P) vaccine in hamsters. Vaccinated hamsters developed high titers of antibodies that could neutralize different variants of the virus and showed reduced disease symptoms after infection. Additionally, the vaccine reduced lung pathology and proinflammatory cytokine levels.
FRONTIERS IN IMMUNOLOGY
(2023)
Article
Multidisciplinary Sciences
Robert J. Fischer, Neeltje van Doremalen, Danielle R. Adney, Claude Kwe Yinda, Julia R. Port, Myndi G. Holbrook, Jonathan E. Schulz, Brandi N. Williamson, Tina Thomas, Kent Barbian, Sarah L. Anzick, Stacy Ricklefs, Brian J. Smith, Dan Long, Craig Martens, Greg Saturday, Emmie de Wit, Sarah C. Gilbert, Teresa Lambe, Vincent J. Munster
Summary: The study demonstrates the effectiveness of the ChAdOx1 nCoV-19 vaccine against clinical disease caused by B.1.1.7 or B.1.351 variants. Vaccinated hamsters did not experience weight loss or lung lesions compared to control animals after being challenged with the variants.
NATURE COMMUNICATIONS
(2021)
Article
Immunology
Bao-Zhong Zhang, Xiaolei Wang, Shuofeng Yuan, Wenjun Li, Ying Dou, Vincent Kwok-Man Poon, Chris Chung-Sing Chan, Jian-Piao Cai, Kenn KaHeng Chik, Kaiming Tang, Chris Chun-Yiu Chan, Ye-Fan Hu, Jing-Chu Hu, Smaranda Ruxandra Badea, Hua-Rui Gong, Xuansheng Lin, Hin Chu, Xuechen Li, Kelvin Kai-Wang To, Li Liu, Zhiwei Chen, Ivan Fan-Ngai Hung, Kwok Yung Yuen, Jasper Fuk-Woo Chan, Jian-Dong Huang
Summary: The S-ID vaccine candidate induced better neutralizing antibody response and showed reduced body weight loss, lung viral load, and histopathological changes in hamsters, suggesting its potential as an effective COVID-19 vaccine.
EMERGING MICROBES & INFECTIONS
(2021)
Article
Immunology
Dennis Christensen, Charlotta Polacek, Daniel J. Sheward, Leo Hanke, Gerald McInerney, Ben Murrell, Katrine Top Hartmann, Henrik Elvang Jensen, Julie Zimmermann, Gregers Jungersen, Kristin Engelhart Illigen, Louise Krag Isling, Carlota Fernandez-Antunez, Santseharay Ramirez, Jens Bukh, Gabriel Kristian Pedersen
Summary: In this study, the SARS-CoV-2 HexaPro spike protein formulated in Alhydrogel was evaluated in Syrian hamsters. Both the accelerated two dose regimen and standard regimen induced similar antibody responses, but low virus neutralization was observed. However, the accelerated regimen provided reduction in viral load and protected against lung pathology upon challenge with homologous SARS-CoV-2 virus.
FRONTIERS IN IMMUNOLOGY
(2023)
Article
Immunology
Susan Johnson, Clarissa Martinez, Sarah N. Tedjakusuma, Nadine Peinovich, Emery G. Dora, Sharla M. Birch, Adriana E. Kajon, Adam D. Werts, Sean N. Tucker
Summary: The study showed that the oral vaccine candidate VXA-CoV2-1 provided protection against SARS-CoV-2 in Syrian hamsters, reducing weight loss and lung pathology, and completely eliminating infectious virus 5 days postchallenge. Oral immunization induced antispike immunoglobulin G and neutralizing antibodies, demonstrating neutralizing activity.
JOURNAL OF INFECTIOUS DISEASES
(2022)
Article
Microbiology
Shanna S. Leventhal, Chad Clancy, Jesse Erasmus, Heinz Feldmann, David W. Hawman
Summary: The study evaluated a DNA vaccine against SARS-CoV-2 in Syrian hamsters, showing significant antibody responses and reduced viral loads, but inability to completely prevent lung pathology. The combination of intramuscular and intranasal vaccine administration did not show clear effectiveness in reducing lung viral titers or pathology.
Article
Multidisciplinary Sciences
Sham Nambulli, Yufei Xiang, Natasha L. Tilston-Lunel, Linda J. Rennick, Zhe Sang, William B. Klimstra, Douglas S. Reed, Nicholas A. Crossland, Yi Shi, W. Paul Duprex
Summary: The study demonstrates the high efficacy of PiN-21 in preventing and treating SARS-CoV-2 infection in Syrian hamsters modeling moderate to severe COVID-19. Intranasal delivery of PiN-21 effectively protects infected animals from weight loss and reduces viral burdens in both lower and upper airways.
Article
Microbiology
Kuandyk Zhugunissov, Kunsulu Zakarya, Berik Khairullin, Mukhit Orynbayev, Yergali Abduraimov, Markhabat Kassenov, Kulyaisan Sultankulova, Aslan Kerimbayev, Sergazy Nurabayev, Balzhan Myrzakhmetova, Aziz Nakhanov, Ainur Nurpeisova, Olga Chervyakova, Nurika Assanzhanova, Yerbol Burashev, Muratbay Mambetaliyev, Moldir Azanbekova, Syrym Kopeyev, Nurlan Kozhabergenov, Aisha Issabek, Moldir Tuyskanova, Lespek Kutumbetov
Summary: Researchers isolated SARS-CoV-2 virus from patients and developed a whole virion inactivated candidate vaccine based on this virus, which was studied for safety and protective effectiveness in Syrian hamsters.
FRONTIERS IN MICROBIOLOGY
(2021)
Article
Immunology
Eszter Somogyi, Mariann Kremlitzka, Zsolt Csiszovszki, Levente Molnar, Orsolya Lorincz, Jozsef Toth, Leon de Waal, Sofie Pattijn, Wencke Reineking, Andreas Beineke, Eniko R. Toke
Summary: This study evaluated the T cell responses and protective efficacy of a peptide-based T cell vaccine, PolyPEPI-SCoV-2, against severe COVID-19 in pre- and post-exposure settings. The vaccine induced robust T cell activation and provided significant protection against disease symptoms and lung damage. The findings demonstrate the contribution of T cell immunity in COVID-19 and support post-exposure prophylaxis as an alternative vaccination strategy.
FRONTIERS IN IMMUNOLOGY
(2023)
Article
Immunology
Kathryn McGuckin Wuertz, Erica K. Barkei, Wei-Hung Chen, Elizabeth J. Martinez, Ines Lakhal-Naouar, Linda L. Jagodzinski, Dominic Paquin-Proulx, Gregory D. Gromowski, Isabella Swafford, Akshaya Ganesh, Ming Dong, Xiankun Zeng, Paul Thomas, Rajeshwer S. Sankhala, Agnes Hajduczki, Caroline E. Peterson, Caitlin Kuklis, Sandrine Soman, Lindsay Wieczorek, Michelle Zemil, Alexander Anderson, Janice Darden, Heather Hernandez, Hannah Grove, Vincent Dussupt, Holly Hack, Rafael de la Barrera, Stasya Zarling, James F. Wood, Jeffrey W. Froude, Matthew Gagne, Amy R. Henry, Elham Bayat Mokhtari, Prakriti Mudvari, Shelly J. Krebs, Andrew S. Pekosz, Jeffrey R. Currier, Swagata Kar, Maciel Porto, Adrienne Winn, Kamil Radzyminski, Mark G. Lewis, Sandhya Vasan, Mehul Suthar, Victoria R. Polonis, Gary R. Matyas, Eli A. Boritz, Daniel C. Douek, Robert A. Seder, Sharon P. Daye, Mangala Rao, Sheila A. Peel, M. Gordon Joyce, Diane L. Bolton, Nelson L. Michael, Kayvon Modjarrad
Summary: The study demonstrates that the use of SpFN-ALFQ vaccine provides protection against SARS-CoV-2-induced disease and viral replication, reducing lung pathology and viral burden.
Article
Microbiology
Chi-Ju Hsu, Wen-Chin Lin, Yu-Ching Chou, Chuen-Mi Yang, Hsueh-Ling Wu, Yun-Hsiang Cheng, Ping-Cheng Liu, Jia-Yu Chang, Hsing-Yu Chen, Jun-Ren Sun
Summary: This study investigates the long-term lung pathology and blood chemistry changes in Syrian hamsters infected with SARS-CoV-2. It found that the virus has an acute onset and recovery course, causing lung damage and long-term changes in blood biochemistry. These findings are important for understanding the long-term health consequences of COVID-19.
MICROBIOLOGY SPECTRUM
(2022)
Article
Immunology
Joan E. M. van der Lubbe, Sietske K. Rosendahl Huber, Aneesh Vijayan, Liesbeth Dekking, Ella van Huizen, Jessica Vreugdenhil, Ying Choi, Miranda R. M. Baert, Karin Feddes-de Boer, Ana Izquierdo Gil, Marjolein van Heerden, Tim J. Dalebout, Sebenzile K. Myeni, Marjolein Kikkert, Eric J. Snijder, Leon de Waal, Koert J. Stittelaar, Jeroen T. B. M. Tolboom, Jan Serroyen, Leacky Muchene, Leslie van der Fits, Lucy Rutten, Johannes P. M. Langedijk, Dan H. Barouch, Hanneke Schuitemaker, Roland C. Zahn, Frank Wegmann
Summary: This study investigated the immunogenicity, protective efficacy, and potential for vaccine-associated enhanced respiratory disease (VAERD) mediated by Ad26.COV2.S in a Syrian hamster challenge model with the G614 spike SARS-CoV-2 variant. Results showed that higher vaccine doses elicited substantial neutralizing antibodies titers and provided complete protection against lung infection and pneumonia in over 80% of Syrian hamsters inoculated with SARS-CoV-2.
Article
Immunology
Petra Mooij, Juan Garcia-Arriaza, Patricia Perez, Adrian Lazaro-Frias, Babs E. Verstrepen, Kinga P. Boszormenyi, Daniella Mortier, Zahra Fagrouch, Gwendoline Kiemenyi-Kayere, Henk Niphuis, Roja Fidel Acar, Lisette Meijer, Marieke A. Stammes, Ivanela Kondova, Ernst J. Verschoor, Corine H. GeurtsvanKessel, Erwin de Bruin, Reina S. Sikkema, Joanna Luczkowiak, Rafael Delgado, Dolores Montenegro, Eugenia Puentes, Esteban Rodriguez, Willy M. J. M. Bogers, Gerrit Koopman, Mariano Esteban
Summary: This study demonstrates that a modified vaccinia virus Ankara (MVA) vector expressing a full-length SARS-CoV-2 spike (S) protein (MVA-S) vaccine has good safety and high immunogenicity in rhesus macaques. Vaccination with MVA-S can induce neutralizing antibodies against SARS-CoV-2 and its variants, reduce viral loads, and alleviate lung pathology caused by the disease. The findings support the potential use of MVA-S as a vaccine for SARS-CoV-2 in clinical trials.
FRONTIERS IN IMMUNOLOGY
(2022)
Article
Multidisciplinary Sciences
Flavia Chiuppesi, Marcela d'Alincourt Salazar, Heidi Contreras, Vu H. Nguyen, Joy Martinez, Yoonsuh Park, Jenny Nguyen, Mindy Kha, Angelina Iniguez, Qiao Zhou, Teodora Kaltcheva, Roman Levytskyy, Nancy D. Ebelt, Tae Hyuk Kang, Xiwei Wu, Thomas F. Rogers, Edwin R. Manuel, Yuriy Shostak, Don J. Diamond, Felix Wussow
NATURE COMMUNICATIONS
(2020)
Article
Immunology
Felix Wussow, Mindy Kha, Taehyun Kim, Minh Ly, Marcal Yll-Pico, Swagata Kar, Mark G. G. Lewis, Flavia Chiuppesi, Don J. J. Diamond
Summary: Researchers developed a vaccine called COH04S1, which provides protection against SARS-CoV-2 Omicron subvariants and other variants. The vaccine has shown safety and immunogenicity in animal models and clinical trials. The study demonstrates the efficacy of COH04S1 and variant-specific vaccines in providing cross-protective immunity.